A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Condition: Ovarian Cancer Interventions: Drug: Olaparib; Drug: Ceralasertib; Drug: Placebo to match olaparib Sponsors: AstraZeneca; Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials